BRPI0519057A2 - derivados de hidantoÍna éteis como inibidores de metaloproteinase - Google Patents

derivados de hidantoÍna éteis como inibidores de metaloproteinase

Info

Publication number
BRPI0519057A2
BRPI0519057A2 BRPI0519057-6A BRPI0519057A BRPI0519057A2 BR PI0519057 A2 BRPI0519057 A2 BR PI0519057A2 BR PI0519057 A BRPI0519057 A BR PI0519057A BR PI0519057 A2 BRPI0519057 A2 BR PI0519057A2
Authority
BR
Brazil
Prior art keywords
derivatives useful
hydantoin derivatives
metalloproteinase inhibitors
inhibitors
methroproteinase
Prior art date
Application number
BRPI0519057-6A
Other languages
English (en)
Inventor
David Walterson
David Jonas Persson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0519057A2 publication Critical patent/BRPI0519057A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

DERIVADOS DE HIDANTOÍNA éTEIS COMO INIBIDORES DE METALOPROTEINASE. A invenção refere-se a um composto de Fórmula (I) onde R¹ é um alquil (C2-4) e é substituído por dois ou mais 2 grupos fluor e R é metil ou etíl, ou um sal farmaceuticamente aceitável deste; a processos para sua preparação, a composições farmacêuticas os contendo e a seu uso no tratamento de doenças ou condições médicas mediadas por enzimas inetaloproteinase.
BRPI0519057-6A 2004-12-15 2005-12-14 derivados de hidantoÍna éteis como inibidores de metaloproteinase BRPI0519057A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0427403.1A GB0427403D0 (en) 2004-12-15 2004-12-15 Novel compounds I
PCT/GB2005/004811 WO2006064218A1 (en) 2004-12-15 2005-12-14 Hydantoin derivatives useful as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0519057A2 true BRPI0519057A2 (pt) 2008-12-23

Family

ID=34090044

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519057-6A BRPI0519057A2 (pt) 2004-12-15 2005-12-14 derivados de hidantoÍna éteis como inibidores de metaloproteinase

Country Status (30)

Country Link
US (1) US8129412B2 (pt)
EP (1) EP1828166B1 (pt)
JP (1) JP5042849B2 (pt)
KR (1) KR20070090921A (pt)
CN (1) CN101080402B (pt)
AR (1) AR051797A1 (pt)
AU (1) AU2005315459B2 (pt)
BR (1) BRPI0519057A2 (pt)
CA (1) CA2589525A1 (pt)
CY (1) CY1109376T1 (pt)
DE (1) DE602005015617D1 (pt)
DK (1) DK1828166T3 (pt)
ES (1) ES2328836T3 (pt)
GB (1) GB0427403D0 (pt)
HK (1) HK1108435A1 (pt)
HR (1) HRP20090489T1 (pt)
IL (1) IL183590A0 (pt)
MX (1) MX2007006744A (pt)
NO (1) NO20073550L (pt)
NZ (1) NZ555684A (pt)
PL (1) PL1828166T3 (pt)
PT (1) PT1828166E (pt)
RS (1) RS51193B (pt)
RU (1) RU2388758C2 (pt)
SA (1) SA05260406B1 (pt)
SI (1) SI1828166T1 (pt)
TW (1) TW200634001A (pt)
UA (1) UA89067C2 (pt)
WO (1) WO2006064218A1 (pt)
ZA (1) ZA200705068B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818006B8 (pt) 2007-10-19 2021-05-25 Boehringer Ingelheim Int compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas
WO2009138777A1 (en) * 2008-05-12 2009-11-19 Astrazeneca Ab Process for the preparation of alkoxy-phenoxy-pi peridine
US7759512B2 (en) 2008-07-21 2010-07-20 3M Innovative Properties Company Aqueous methods for making fluorinated sulfonate esters
CN102234287B (zh) 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
MY167881A (en) 2010-07-16 2018-09-26 Abbvie Bahamas Ltd Process for preparing antiviral compounds
MX338725B (es) 2010-07-16 2016-04-28 Abbvie Bahamas Ltd Ligando de fosfina para reacciones cataliticas.
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
US20160364553A1 (en) * 2015-06-09 2016-12-15 Intel Corporation System, Apparatus And Method For Providing Protected Content In An Internet Of Things (IOT) Network
GB201610056D0 (en) * 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP2003501414A (ja) * 1999-06-04 2003-01-14 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤
WO2001062742A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0301922D0 (sv) 2003-06-27 2003-06-27 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
TW200634001A (en) 2006-10-01
CY1109376T1 (el) 2014-07-02
HRP20090489T1 (hr) 2009-10-31
EP1828166B1 (en) 2009-07-22
RU2388758C2 (ru) 2010-05-10
SA05260406B1 (ar) 2009-02-02
JP2008524184A (ja) 2008-07-10
AU2005315459A1 (en) 2006-06-22
HK1108435A1 (en) 2008-05-09
WO2006064218A1 (en) 2006-06-22
US8129412B2 (en) 2012-03-06
DK1828166T3 (da) 2009-10-05
RS51193B (sr) 2010-10-31
RU2007121222A (ru) 2009-01-27
ZA200705068B (en) 2008-10-29
SI1828166T1 (sl) 2009-12-31
JP5042849B2 (ja) 2012-10-03
CA2589525A1 (en) 2006-06-22
CN101080402B (zh) 2010-12-08
EP1828166A1 (en) 2007-09-05
NO20073550L (no) 2007-09-11
US20080280950A1 (en) 2008-11-13
AU2005315459B2 (en) 2009-01-08
GB0427403D0 (en) 2005-01-19
MX2007006744A (es) 2007-07-09
IL183590A0 (en) 2007-09-20
PL1828166T3 (pl) 2009-12-31
ES2328836T3 (es) 2009-11-18
DE602005015617D1 (de) 2009-09-03
CN101080402A (zh) 2007-11-28
PT1828166E (pt) 2009-09-16
KR20070090921A (ko) 2007-09-06
AR051797A1 (es) 2007-02-07
UA89067C2 (ru) 2009-12-25
NZ555684A (en) 2009-11-27

Similar Documents

Publication Publication Date Title
BRPI0519057A2 (pt) derivados de hidantoÍna éteis como inibidores de metaloproteinase
BRPI0407618A (pt) derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
BR0010520A (pt) Novos compostos farmaceuticamente ativos
MA31685B1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
HRP20090459T1 (hr) Aminofenil derivati kao novi inhibitori histonskih deacetilaza
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
BRPI0517263A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
BRPI0512252A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0512986A (pt) novos derivados de hidantoìna
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0706992C8 (pt) composto de fórmula (i) e formulação farmacêutica
BRPI0517259A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
BRPI0809542A8 (pt) Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.